currencies funds- Top Knowledge

Two States in the United States sued Glock, a gun manufacturer, for ignoring the design flaw that "pistols can easily become machine guns". On the 12th, the prosecutors in New Jersey and Minnesota respectively sued Glock, an Austrian weapons manufacturer, accusing the pistol manufactured by them of design defects and being easily converted into illegal machine guns. According to the complaint, Glock knew this situation for a long time, and continued to sell this pistol to the United States and profit from it, which promoted the proliferation of gun violence in the United States. (Xinhua News Agency)Market news: Sam Altman, founder of OpenAI, will donate $1 million to the inauguration fund of President-elect Trump. According to reports, Altman plans to donate to the Presidential Inaugural Committee in his own name, instead of directly donating by OpenAI.GCL Technology: It is estimated that there will be no more share repurchase cancellation in 2024. GCL Technology (03800) announced that in view of the fact that the photovoltaic industry is still in excessive competition, in order to ensure the stability of the company's operation and cope with the uncertainty in the future, the company expects that there will be no more share repurchase cancellation in the year ending December 31, 2024.

Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, while Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, accounting for 0.58% of the total turnover of the day. The average transaction price was 255 yuan, which was 4.51% lower than the market closing price of 267.03 yuan, of which the highest transaction price was 267.03 yuan and the lowest transaction price was 218.97 yuan.Analysis: the potential weakness of Canada's manufacturing industry still exists. Forexlive: Canada's manufacturing industry rebounded strongly, mainly driven by petroleum products and automobiles. However, the year-on-year data decline shows that some potential weakness still exists.Peng Qinghua met with Babacov, Vice Chairman of Russian State Duma, and Peng Qinghua, Vice Chairman of the National People's Congress Standing Committee (NPCSC), met with Babacov, Vice Chairman of Russian State Duma, in Beijing on the 13th. The two sides indicated that they will jointly implement the important consensus reached by the two heads of state, make good use of the platform of the joint working group of the Sino-Russian Parliamentary Cooperation Committee, deepen exchanges and cooperation between legislative bodies, and promote the further development of China-Russia comprehensive strategic partnership of cooperation in the new era. (Xinhua News Agency)

Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.Huitai Medical: Using raised funds and self-owned funds to increase capital of 700 million yuan to wholly-owned subsidiaries. Huitai Medical announced that the company held the 20th meeting of the second board of directors and the 17th meeting of the second board of supervisors on December 12, 2024, and reviewed and approved the Proposal on Using raised funds and self-owned funds to increase capital to wholly-owned subsidiaries. The company agreed to increase its capital by 700 million yuan to Shanghai Hongtong Industrial Co., Ltd., a wholly-owned subsidiary, of which 438 million yuan of interest-bearing loans provided to Shanghai Hongtong with raised funds were converted into capital increase, and 262 million yuan was increased with its own funds. After the capital increase is completed, the registered capital of Shanghai Hongtong will increase from RMB 18,489,300 to RMB 26,548,200, and it will remain a wholly-owned subsidiary of the company.Huabei Pharmaceutical Co., Ltd.: Four kinds of drugs under the company are planned to be selected for national centralized drug procurement. Huabei Pharmaceutical announced that the company and its subsidiary Xiantai Company participated in the tenth batch of national centralized drug procurement, and all four varieties are planned to be selected, including penicillin sodium for injection, piperacillin sodium for injection, ampicillin sodium for injection and sulbactam sodium for injection. The price of the drug to be selected this time has decreased compared with the original sales price. In 2023, the sales income of penicillin sodium for injection was 129 million yuan, accounting for 1.28% of the annual operating income. If the bid is confirmed and the purchase and sale contract is signed, the company will fully guarantee the supply according to the demand of the selected area, and promote the increment of related products in the selected area and the development of the off-standard market.